DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Follow-Up Questions
Dbv Technologies SA (DBVT) 的本益比是多少？
Dbv Technologies SA 的本益比是 N/A
Dbv Technologies SA 的 CEO 是誰？
Mr. Daniel Tasse 是 Dbv Technologies SA 的 Chief Executive Officer，自 2018 加入公司。
DBVT 股票的價格表現如何？
DBVT 的當前價格為 9.73，在上個交易日 decreased 了 1.4%。
Dbv Technologies SA 的主要業務主題或行業是什麼？
Dbv Technologies SA 屬於 Biotechnology 行業，該板塊是 Health Care
